2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task …

JL Zamorano, P Lancellotti… - European heart …, 2016 - academic.oup.com
The task of developing CPG documents covers not only integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European …

AR Lyon, E Bossone, B Schneider… - European journal of …, 2016 - Wiley Online Library
Takotsubo syndrome is an acute reversible heart failure syndrome that is increasingly
recognized in modern cardiology practice. This Position Statement from the European …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology

JR Ghadri, IS Wittstein, A Prasad… - European heart …, 2018 - academic.oup.com
Takotsubo syndrome (TTS) is a poorly recognized heart disease that was initially regarded
as a benign condition. Recently, it has been shown that TTS may be associated with severe …

Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy

A Gulati, A Jabbour, TF Ismail, K Guha, J Khwaja… - Jama, 2013 - jamanetwork.com
Importance Risk stratification of patients with nonischemic dilated cardiomyopathy is
primarily based on left ventricular ejection fraction (LVEF). Superior prognostic factors may …

2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and …

TA McDonagh, M Metra, M Adamo… - European Heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Branching Fraction and Photon Energy Spectrum for

S Chen, JW Hinson, J Lee, DH Miller, V Pavlunin… - Physical Review Letters, 2001 - APS
We have measured the branching fraction and photon energy spectrum for the radiative
penguin process b→ s γ. We find B (b→ s γ)=(3.21±0.43±0.27− 0.10+ 0.18)× 10− 4, where …

Stress (Takotsubo) cardiomyopathy—a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning

AR Lyon, PSC Rees, S Prasad… - Nature clinical practice …, 2008 - nature.com
Stress cardiomyopathy, also referred to as Takotsubo cardiomyopathy, is an increasingly
recognized clinical syndrome characterized by acute reversible apical ventricular …